About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker TRAW · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 6, 2026Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to M…
NCT07157007 · COVID - 19
Ratutrelvir (83-0060) non-randomised, Paxlovid
TRAW
Traws Pharma, Inc.
Phase 2Completed
was recruiting
93Feb 16, 2026Registry ↗
Aug 3, 2026Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
NCT07526506 · Healthy Volunteer
TRX-100, Placebo
TRAW
Traws Pharma, Inc.
Phase 1Recruiting32Sep 2026Registry ↗
Mar 31, 2026Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
NCT07503405 · Influenza
TRX-100, Placebo
TRAW
Traws Pharma, Inc.
Phase 2Not yet recruiting165Nov 2026Registry ↗
Mar 27, 2026This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil…
NCT07371650 · Influenza
TRX-100, Standard of Care (SOC)
TRAW
Traws Pharma, Inc.
Phase 2Active, not recruiting105Dec 2026Registry ↗
Jan 22, 2026Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-…
NCT06402136 · Healthy Volunteers Only
83-0060, Placebo
TRAW
Traws Pharma, Inc.
Phase 1Completed57Aug 9, 2024Registry ↗
Jan 21, 2026A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TR…
NCT06757738 · Healthy Volunteer Study
TRX-100, Placebo
TRAW
Traws Pharma, Inc.
Phase 1Completed66Jan 16, 2025Registry ↗
Dec 12, 2023Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malign…
NCT05705505 · Endometrioid Endometrial Cancer
Narazaciclib, Letrozole 2.5mg
TRAW
Traws Pharma, Inc.
Phase 1/2Unknown60Jan 2026Registry ↗
Dec 7, 2023Study of ON 123300 in Patients With Advanced Cancer
NCT04739293 · Solid Tumors, Adult
ON123300
TRAW
Traws Pharma, Inc.
Phase 1Unknown36Oct 2024Registry ↗
Sep 26, 2022Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure…
NCT02562443 · Myelodysplastic Syndrome, MDS
rigosertib, Any approved or standard-of-care therapy
TRAW
Traws Pharma, Inc.
Phase 3Terminated372Jul 26, 2020Registry ↗
Jun 22, 2021Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
NCT02168725 · Neoplasms, Advanced Solid Tumor
briciclib
TRAW
Traws Pharma, Inc.
Phase 1Terminated26Dec 2015Registry ↗
Jun 16, 2021Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
NCT01926587 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
oral rigosertib, Azacitidine
TRAW
Traws Pharma, Inc.
Phase 1/2Completed45Dec 8, 2020Registry ↗
Jun 16, 2021Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
NCT01904682 · Myelodysplastic Syndromes
Oral rigosertib
TRAW
Traws Pharma, Inc.
Phase 2Completed45Dec 2020Registry ↗
Jul 1, 2020Three Dosing Schedules of Oral Rigosertib in MDS Patients
NCT02075034 · Myelodysplastic Syndrome
rigosertib
TRAW
Traws Pharma, Inc.
Phase 1Withdrawn0Aug 2019Registry ↗
Jun 30, 2020Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidi…
NCT01928537 · Myelodysplastic Syndromes, Refractory Anemia With Excess Bl…
rigosertib sodium
TRAW
Traws Pharma, Inc.
Phase 3Completed67Jun 29, 2017Registry ↗
Jun 30, 2020Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
NCT01241500 · Myelodysplastic Syndromes, MDS
ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 3Completed299Oct 3, 2018Registry ↗
Jan 10, 2018Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
NCT00854646 · Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 1Completed22Nov 2014Registry ↗
Jul 21, 2017Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
NCT00856791 · Ovarian Cancer
ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 2Completed1Jul 2011Registry ↗
Jun 26, 2017Oral Rigosertib for Squamous Cell Carcinoma
NCT01807546 · Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell C…
rigosertib
TRAW
Traws Pharma, Inc.
Phase 2Completed64Mar 2015Registry ↗
Jun 26, 2017Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 My…
NCT01584531 · Myelodysplastic Syndrome, MDS
rigosertib
TRAW
Traws Pharma, Inc.
Phase 2Completed82May 2015Registry ↗
Jun 26, 2017Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML)…
NCT01167166 · Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
rigosertib
TRAW
Traws Pharma, Inc.
Phase 1/2Completed30Dec 2013Registry ↗
Jun 26, 2017Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Cla…
NCT00906334 · Myelodysplastic Syndrome
ON 01910.Na, ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 2Completed14Nov 2013Registry ↗
Jun 26, 2017Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
NCT00854945 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 1/2Completed36Sep 2013Registry ↗
Jun 23, 2017Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02107235 · Head and Neck Neoplasms, Carcinoma, Squamous Cell
oral rigosertib, cisplatin
TRAW
Traws Pharma, Inc.
Phase 1Completed2Oct 2014Registry ↗
Jun 23, 2017Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
NCT02030639 · Healthy
rigosertib
TRAW
Traws Pharma, Inc.
Phase 1Completed6Dec 2014Registry ↗
Jun 23, 2017Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
NCT01538563 · Solid Tumors, Advanced Cancer
rigosertib sodium
TRAW
Traws Pharma, Inc.
Phase 1Completed42Jul 2010Registry ↗
Jun 23, 2017Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
NCT01538537 · Advanced Cancer, Solid Tumors
rigosertib sodium
TRAW
Traws Pharma, Inc.
Phase 1Completed29Oct 2010Registry ↗
Jun 23, 2017Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
NCT01168011 · Solid Tumor
rigosertib
TRAW
Traws Pharma, Inc.
Phase 1Completed68Dec 2015Registry ↗
Jun 23, 2017Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
NCT01165905 · Solid Tumor
ON 01910.Na, Gemcitabine
TRAW
Traws Pharma, Inc.
Phase 1Completed10Jul 2011Registry ↗
Jun 23, 2017Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
NCT01125891 · Malignant Neoplasmas, Solid Tumors
gemcitabine, ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 1Completed39Sep 2011Registry ↗
Jun 23, 2017Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
NCT01048619 · Myelodysplastic Syndrome
ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 1Completed36Nov 2014Registry ↗
Jun 23, 2017Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplast…
NCT00867061 · Myelodysplastic Syndrome
ON 01910.Na Concentrate
TRAW
Traws Pharma, Inc.
Phase 1/2Withdrawn0Jun 2010Registry ↗
Jun 23, 2017Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
NCT00861783 · Hepatoma, Advanced Solid Tumor
irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na
TRAW
Traws Pharma, Inc.
Phase 1Completed16Jul 2011Registry ↗
Jun 23, 2017Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
NCT00861328 · Advanced Solid Tumors
ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin
TRAW
Traws Pharma, Inc.
Phase 1Completed18Jul 2011Registry ↗
Aug 4, 2016Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
NCT01360853 · Metastatic Pancreatic Adenocarcinoma
ON 01910.Na, Gemcitabine
TRAW
Traws Pharma, Inc.
Phase 3Completed160Jun 2015Registry ↗
Dec 8, 2015Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
NCT01049113 · Lymphoma, Acute Lymphocytic Leukemia
ON 013105
TRAW
Traws Pharma, Inc.
Phase 1Terminated7Dec 2014Registry ↗

35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:26 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances